Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension
Patent No. EP3897646 (titled "Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension") was filed by Actelion Pharmaceuticals on Dec 20, 2019. The application was issued on May 22, 2024.
Patent Summary
A combination therapy for pulmonary arterial hypertension (PAH) that targets patients with mild to moderate disease. The treatment involves administering macitentan at a high dose of 60-90 mg/day, with a preferred regimen of 75 mg/day. This combination therapy combines macitentan with phosphodiesterase type 5 inhibitors (PDE5is) and prostacyclin analogues, offering improved disease control and potential long-term benefits over traditional treatments.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3897646
- Application Number
- EP19832954A
- Filing Date
- Dec 20, 2019
- Status
- Granted And Under Opposition
- Apr 19, 2024
- Publication Date
- May 22, 2024
- External Links
- Slate, Register , Google Patents